Fortress Biotech, Inc. (FBIO)

Fortress Biotech's stock price has increased by 116.49% over the past six months. The stock price increased by 46.26% in the past month and 111.82% over the last 12 months. Shares surged approximately 10% on January 13, 2026, following the FDA's approval of ZYCUBO (CUTX-101) for treating Menkes disease in children. On December 15, 2025, Fortress Biotech and Cyprium Therapeutics announced the FDA's acceptance of the CUTX-101 New Drug Application (NDA) resubmission. On November 14, 2025, Fortress Biotech reported its Third Quarter 2025 financial results, showing higher revenue and a swing to net income. Journey Medical Corporation, a subsidiary, also reported Q3 2025 revenue growth and improved margins on November 12, 2025. On December 10, 2025, Journey Medical Corporation announced the publication of clinical trial results for Emrosi™ (DFD-29), which met microbiological endpoints with no safety issues.

Information regarding specific demand seasonality for Fortress Biotech, Inc.'s products and services is not readily available. Demand for their products might be less subject to typical consumer seasonality and more driven by disease prevalence, treatment cycles, and market access.

Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring, developing, and commercializing pharmaceutical and biotechnology products. The company operates in the healthcare sector, specifically in the biotechnology industry, and expands its portfolio through licensing, partnerships, and joint ventures. Fortress Biotech's product portfolio includes marketed dermatology products and development-stage candidates across oncology, rare diseases, and gene therapy. Major marketed dermatology products include Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, Exelderm, Emrosi and Luxamend. Key late-stage product candidates include ZYCUBO (CUTX-101), Intravenous Tramadol, UNLOXCYT, Olafertinib, CAEL-101 and Triplex. Early-stage and preclinical product candidates cover areas such as gout, glioblastoma, B-cell non-Hodgkin lymphoma, gene therapies, and various inhibitors and modulators.

Fortress Biotech, Inc. was incorporated in Delaware, US, in 2006 and is headquartered in Bay Harbor Islands, Florida.

Fortress Biotech's brand reputation has been positively impacted by recent regulatory successes and financial performance. The FDA approval of ZYCUBO (CUTX-101) for Menkes disease is a significant positive event, as it is the first and only approved treatment for this rare pediatric disease in the U.S. The FDA's acceptance of the NDA resubmission for CUTX-101 demonstrates progress in their development pipeline. Positive Q3 2025 financial results, including increased revenue and a swing to profitability, contribute to a favorable perception. The company's strategic acquisition of Checkpoint Therapeutics and the anticipated success of Emrosi are also seen as positive indicators for future growth and financial stability.

Fortress Biotech (FBIO) stock ownership is a mix of institutional, insider, and retail investors. Approximately 8.52% to 14.44% of the company's stock is owned by institutional investors, while insiders hold around 4.02% to 48.94%. Retail investors hold a significant portion, estimated at 36.90% to 84.29%. Major institutional owners include Vanguard Group Inc., Vanguard Total Stock Market Index Fund Investor Shares (VTSMX), Summit Financial, LLC, Susquehanna International Group, Llp, Shikiar Asset Management Inc, Vanguard Extended Market Index Fund Investor Shares (VEXMX), Geode Capital Management, Llc, Northern Trust Corp, Sculptor Capital LP and Blackrock, Inc. Major individual owners (insiders) include Lindsay A. Md Rosenwald, Elliott Associates LP, Michael S. Weiss, Elliott International LP, David Jin and George Avgerinos.